Beata Mladosievičová, Ján Rajec
The multimodal oncological therapy includes use of multiple therapeutical modalities to achieve higher effectiveness. In the best case it means long term survival, respectively the cure of the patient. Except for surgery, radiotherapy and classical cytostatics, the targeted therapy has currently become the standard in the management of various malignancies. Those are drugs with more specific acting on target molecules located in malignant cells. The application of cytostatic drugs is due to their non-specific acting associated with a lot of side effects. It is necessary to admit that we also face various toxicities when using biological drugs, though with different profile comparing to chemotherapy. One of the most serious side effects is cardiotoxicity. It may be the sequel of radiotherapy, chemotherapy and quite often also of the targeted therapy. The risk is increasing when using more therapeutical approaches together. Best described and in several aspects still unclear is the cardiotoxicity of anthracyclines, from biological drugs the cardiotoxicity of trastuzumab.